cisplatin,pemetrexed,pembrolizumab,gemcitabine
merck
['key,note,62', 'keynote,671', 'keynote 671', 'pembro']
this is impressive. efs benefit with perioperative pembrolizumab in keynote 671 at #asco23. hr here 0.58 with mefs not reached with median fu 2y. 1y efs rate 73% vs 60%; 2y efs rate 62%vs 41%. important that the efs curves widen over time. benefit of adjuvant pembrolizumab here? 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo